Demerx, Inc.

E. R. Squibb Sons, Inc.

Mitotech Sa

Lawrence Friedhoff

Maxim Vladimirovich Skulachev

Vladimir Petrovich Skulachev

Maxim Viktorovich Egorov

Roman A Zinovkin

Vadim N Tashlitsky

Olga Y Pletushkina

Alexander A Andreev-Andrievsky

Tatiana V Zinevich

Gary J Grover

Martin L Ogletree

Emeline Maillet

Holger Weis

Laura Lee Bolton

William A Schumacher

Andrey Aleksandrovich Zamyatnin

Eugeny S Efremov

Audrey A Zamyatnin

Vladimir P Skulachev

Andrey A Zamyatnin

Laura L Bolton

A short treatment with noribogaine shows promise for treating drug dependency. Many opioid addicts are treated with methadone. Giving noribogaine to mammal concurrently being administered methadone surprisingly exacerbates methadone's negative side-effects, and increases the risk of death. Therefore, prior to noribogaine treatment, a patient on methadone therapy undergoes a period of methadone abstinence to wash out the methadone. Surprisingly, noribogaine does not react negatively to morphine. According to the invention, methadone regimen is replaced with morphine prior to noribogaine treatment.

Method for noribogaine treatment in patients on methadone

This invention is directed to a method for pre-screening an opioid-addicted patient to determine the patient's tolerance for a therapeutic dose of noribogaine.

Methods and compositions for pre-screening patients for treatment with noribogaine

Provided are stable liquid and solid formulations of oxidized and reduced mitochondria-targeted antioxidants, and methods of their preparation and use.

Oral formulations of mitochondrially-targeted antioxidants and their preparation and use

This invention provides methods and compositions for treating nicotine addiction or treating or preventing nicotine cravings in a subject. The method comprises administering to the patient in need thereof a therapeutically effective amount of noribogaine, noribogaine derivative, or a pharmaceutically acceptable salt thereof.

Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use

This invention is directed to methods of treating pain in patients comprising treating patients with ibogaine, an ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof at a therapeutic dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL.

Use of ibogaine for the treatment of pain

This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with noribogaine at a dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL (AUC/24 h) under conditions where the QT interval prolongation does not exceed about 50 milliseconds.

Methods for acute and long-term treatment of drug addiction

A method is provided for preventing reducing or reversing adverse reactions, such as pulmonary hypertension produced when protamine interacts with heparin, by administering a thromboxane A.sub.2 receptor antagonist.

Method of preventing or reducing adverse reactions to protamine using a

A method for treating skin injuries is provided by administering a thromboxane A.sub.2 receptor antagonist systemically or topically to the skin area to be treated.

Method of treating skin injuries using thromboxane A.sub.2 receptor

Growing community of inventors

River Vale, NJ, United States of America

Lawrence Friedhoff